1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc.

PTHS
Pelthos Therapeutics Inc.US flagNew York Stock Exchange American
25.88
USD
-0.12
- -
16.78MMarket Cap

Total Valuation

Pelthos Therapeutics Inc. carries a market capitalization of 16.78M, placing it among publicly traded companies globally. Its enterprise value stands at 48.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap16.78M
Enterprise Value48.01M

Share Statistics

Pelthos Therapeutics Inc. currently has 3.37M shares outstanding.

Shares Outstanding3.37M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.93, and the price-to-book ratio stands at -0.71.

PE RatioN/A
PS Ratio1.93
PB Ratio-0.71
P/TBV Ratio-1.91
P/FCF Ratio-1.53
P/OCF Ratio-1.52

Enterprise Valuation

EV / Sales1.73
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Pelthos Therapeutics Inc. maintains a current ratio of 2.79, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 75.71, indicating elevated leverage, while an interest coverage ratio of -7.83 demonstrates limited ability to service its debt obligations.

Current Ratio2.79
Quick Ratio1.75
Debt / Equity75.71
Debt / EBITDA-0.65
Interest Coverage-7.83

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-70.53
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.25

Taxes

Income Tax-7.39M
Effective Tax RateN/A

Stock Price Statistics

Pelthos Therapeutics Inc.'s stock has gained approximately 119.32203% over the past 52 weeks. The 50-day moving average sits at 24.36, while the 200-day moving average is 26.31.

Beta (5Y)N/A
52-Week Price Change119.32203%
50-Day Moving Average24.36
200-Day Moving Average26.31
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Pelthos Therapeutics Inc. generated 27.70M in revenue and converted that into -51.59M in net income, yielding earnings per share of -20.29. EBITDA reached -40.97M, while operating income came in at -43.68M.

Revenue27.70M
Gross Profit13.02M
Operating Income-43.68M
Pretax Income-58.98M
Net Income-51.59M
EBITDA-40.97M
EBIT-43.68M
Earnings Per Share (EPS)-20.29

Balance Sheet

Pelthos Therapeutics Inc. holds 31.98M in cash and equivalents against 26.58M in total debt, resulting in a net debt position of -8.69M. Total book value stands at -75.03M, with working capital of 44.80M providing operational flexibility.

Cash & Cash Equivalents31.98M
Total Debt26.58M
Net Debt-8.69M
Equity (Book Value)-75.03M
Book Value Per Share-29.52
Working Capital44.80M

Cash Flow

Pelthos Therapeutics Inc. produced -35.08M in operating cash flow over the past twelve months. After subtracting -194,000.00 in capital expenditures, free cash flow totaled -35.28M - equivalent to -13.88 per share.

Operating Cash Flow-35.08M
Capital Expenditures-194,000.00
Free Cash Flow-35.28M
FCF Per Share-13.88

Margins

Pelthos Therapeutics Inc. operates with a gross margin of 47.02, reflecting its pricing power and cost economics. The operating margin of -157.70 and net profit margin of -186.23 provide insight into operational efficiency.

Gross Margin47.02
Operating Margin-157.70
Pretax Margin-212.90
Profit Margin-186.23
EBITDA Margin-147.89

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-135.95
FCF Yield-65.33

Stock Splits

Pelthos Therapeutics Inc.'s most recent stock split took place on July 2, 2025 with a 10:1 split ratio.

Last Split Date7/2/2025
Split Ratio10:1

Scores

Pelthos Therapeutics Inc. posts an Altman Z-Score of -1.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.75